CIENCIASMEDICASNEWS: FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma | FDA

jueves, 23 de marzo de 2023

FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma | FDA

FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma | FDA

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)